Advice

following a full submission assessed under the end of life process:

atezolizumab (Tecentriq®) is accepted for use within NHSScotland.

Indication under review: in combination with bevacizumab for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

In a phase III study in patients with advanced or unresectable HCC who had not received prior systemic therapy, atezolizumab plus bevacizumab was associated with greater overall and progression-free survival compared with a multikinase inhibitor.

This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.

Medicine details

Medicine name:
atezolizumab (Tecentriq)
SMC ID:
SMC2349
Indication:

In combination with bevacizumab for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

Pharmaceutical company
Roche
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Accepted
Date advice published
12 July 2021